NASDAQ:CERSCerus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.00 -0.06 (-0.85 %) (As of 08/10/2020 02:36 PM ET) Add Compare Share Today's Range$6.86Now: $7.00▼$7.1650-Day Range$6.18MA: $6.81▼$7.4752-Week Range$2.71Now: $7.00▼$7.56Volume122,195 shsAverage Volume1.70 million shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/ABeta1.29 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.63, Cerus has a potential upside of 8.3% from its current price of $7.04.Amount of Analyst CoverageCerus has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesCerus has received 555 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCerus has received 385 “underperform” votes. (Add your “underperform” vote.)Community SentimentCerus has received 59.04% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote “Outperform” if you believe CERS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,333,550.00 in company stock.Percentage Held by InsidersOnly 6.49% of the stock of Cerus is held by insiders.Percentage Held by Institutions80.07% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.41) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -16.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -16.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 17.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:CERS Previous Symbol CUSIP15708510 CIK1020214 Webwww.cerus.com Phone925-288-6000Debt Debt-to-Equity Ratio0.50 Current Ratio4.15 Quick Ratio3.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$74.65 million Price / Sales15.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book17.07Profitability EPS (Most Recent Fiscal Year)($0.51) Net Income$-71,240,000.00 Net Margins-83.78% Return on Equity-76.83% Return on Assets-34.82%Miscellaneous Employees240 Outstanding Shares166,170,000Market Cap$1.16 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $7.00 -0.06 (-0.85 %) (As of 08/10/2020 02:36 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CERS News and Ratings via Email Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter. Cerus (NASDAQ:CERS) Frequently Asked Questions How has Cerus' stock been impacted by COVID-19 (Coronavirus)? Cerus' stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CERS shares have increased by 48.1% and is now trading at $7.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cerus? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerus. When is Cerus' next earnings date? Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Cerus. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) released its earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%. View Cerus' earnings history. What guidance has Cerus issued on next quarter's earnings? Cerus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million. What price target have analysts set for CERS? 4 brokerages have issued 12-month target prices for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they anticipate Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View analysts' price targets for Cerus. Has Cerus been receiving favorable news coverage? News stories about CERS stock have been trending very positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a news impact score of 3.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Cerus. Who are some of Cerus' key competitors? Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), Quidel (QDEL), DENTSPLY SIRONA (XRAY), Neogen (NEOG), Haemonetics (HAE), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK). View all competitors. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Opko Health (OPK), Grayscale Bitcoin Trust (Btc) (GBTC), ACADIA Pharmaceuticals (ACAD), Aduro BioTech (ADRO) and Celldex Therapeutics (CLDX). Who are Cerus' key executives? Cerus' management team includes the following people: Mr. William M. Greenman, Pres, CEO & Director (Age 52)Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)Dr. Richard J. Benjamin, Chief Medical Officer (Age 59) What is Cerus' stock symbol? Cerus trades on the NASDAQ under the ticker symbol "CERS." Who are Cerus' major shareholders? Cerus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%), UBS Group AG (0.26%) and Swiss National Bank (0.22%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View institutional ownership trends for Cerus. Which institutional investors are selling Cerus stock? CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Premier Asset Management LLC, Raymond James & Associates, Personal CFO Solutions LLC, Leap Investments LP, and Shufro Rose & Co. LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman. View insider buying and selling activity for Cerus. Which institutional investors are buying Cerus stock? CERS stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Raymond James Financial Services Advisors Inc., Trexquant Investment LP, New York State Common Retirement Fund, SG Americas Securities LLC, and Exchange Traded Concepts LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman. View insider buying and selling activity for Cerus. How do I buy shares of Cerus? Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cerus' stock price today? One share of CERS stock can currently be purchased for approximately $7.05. How big of a company is Cerus? Cerus has a market capitalization of $1.17 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe. What is Cerus' official website? The official website for Cerus is www.cerus.com. How can I contact Cerus? Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
